Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dyspeptic symptoms, upper abdominal pain, heartburn, regurgitation;~* Endoscopically - normal appearing GE junction, irregular z-line, or erosive esophagitis up to Grade 2.~Exclusion Criteria:~* Barrett's esophagus (Endoscopically greater than 2 cm of columnar epithelium on endoscopy and the presence of specialized columnar epithelium on histology);~* Patients who have been taking a PPI longer than the 3 months proceeding study entry. Patients currently taking a PPI but for less than 3 months who are not willing to discontinue PPI treatment for 4 weeks prior to enrollment into this study.~* Severe esophagitis Grade 3 or 4~* Documented active duodenal or gastric ulcer (at least 0.5cm diameter). Patients with erosions can be included.~* Presence of esophageal varices~* History of gastric surgery altering normal anatomy (eg, Billroth procedure, gastric bypass)~* Pregnant or nursing patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).